Assessment of Serum Bactericidal and Opsonophagocytic Activity of Antibodies to Gonococcal Vaccine Targets

Evgeny A Semchenko; Freda E-C Jen; Michael P Jennings; Kate L Seib

doi:10.1007/978-1-0716-1900-1_19

Assessment of Serum Bactericidal and Opsonophagocytic Activity of Antibodies to Gonococcal Vaccine Targets

Methods Mol Biol. 2022:2414:363-372. doi: 10.1007/978-1-0716-1900-1_19.

Authors

Evgeny A Semchenko¹, Freda E-C Jen², Michael P Jennings², Kate L Seib³

Affiliations

¹ Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia. e.semchenko@griffith.edu.au.
² Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia.
³ Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia. k.seib@griffith.edu.au.

PMID: 34784046
DOI: 10.1007/978-1-0716-1900-1_19

Abstract

There is no vaccine available to prevent Neisseria gonorrhoeae infection, however there is currently a high level of interest in developing gonococcal vaccines due to the increasing number of cases and continuing emergence of antimicrobial resistance worldwide. A key aspect of vaccine development is the investigation of the functional immune response raised to the vaccine targets under investigation. Here, we describe two assays used to assess the functional immune response raised against gonococcal vaccine targets: the serum bactericidal assay (SBA) and the opsonophagocytic assay (OPA).

Keywords: Antibody; Antigen; Complement; Immune response; N. gonorrhoeae; Neutrophil; Opsonophagocytic assay (OPA); Polymorphonuclear leukocyte (PMN); Serum bactericidal assay (SBA ); Vaccine.

MeSH terms

Antibodies, Bacterial
Bacterial Vaccines
Blood Bactericidal Activity
Gonorrhea* / prevention & control
Humans
Neisseria gonorrhoeae / immunology

Substances

Antibodies, Bacterial
Bacterial Vaccines